|
1
|
Ogawa M, Nakai S, Deguchi A, Nonomura T,
Masaki T, Uchida N, Yoshiji H and Kuriyama S: Vitamins K2, K3 and
K5 exert antitumor effects on established colorectal cancer in mice
by inducing apoptotic death of tumor cells. Int J Oncol.
31:323–331. 2007.PubMed/NCBI
|
|
2
|
Yoshida H, Shiratori Y, Kudo M, Shiina S,
Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, et
al: Effect of vitamin K2 on the recurrence of hepatocellular
carcinoma. Hepatology. 54:532–540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li ZQ, He FY, Stehle CJ, Wang Z, Kar S,
Finn FM and Carr BI: Vitamin K uptake in hepatocytes and hepatoma
cells. Life Sci. 70:2085–2100. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iwamoto J, Takeda T and Sato Y: Effects of
vitamin K2 on osteoporosis. Curr Pharm Des. 10:2557–2576. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ushiroyama T, Ikeda A and Ueki M: Effect
of continuous combined therapy with vitamin K(2) and vitamin D(3)
on bone mineral density and coagulofibrinolysis function in
postmenopausal women. Maturitas. 41:211–221. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bouzahzah B, Nishikawa Y, Simon D and Carr
BI: Growth control and gene expression in a new hepatocellular
carcinoma cell line, Hep40: Inhibitory actions of vitamin K. J Cell
Physiol. 165:459–467. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hitomi M, Yokoyama F, Kita Y, Nonomura T,
Masaki T, Yoshiji H, Inoue H, Kinekawa F, Kurokohchi K, Uchida N,
et al: Antitumor effects of vitamins K1, K2 and K3 on
hepatocellular carcinoma in vitro and in vivo. Int J Oncol.
26:713–720. 2005.PubMed/NCBI
|
|
8
|
Takami A, Nakao S, Ontachi Y, Yamauchi H
and Matsuda T: Successful therapy of myelodysplastic syndrome with
menatetrenone, a vitamin K2 analog. Int J Hematol. 69:24–26.
1999.PubMed/NCBI
|
|
9
|
Fujita H, Tomiyama J and Tanaka T: Vitamin
K2 combined with all-trans retinoic acid induced complete remission
of relapsing acute promyelocytic leukaemia. Br J Haematol.
103:584–585. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yoshiji H, Noguchi R, Yamazaki M, Ikenaka
Y, Sawai M, Ishikawa M, Kawaratani H, Mashitani T, Kitade M, Kaji
K, et al: Combined treatment of vitamin K2 and
angiotensin-converting enzyme inhibitor ameliorates hepatic
dysplastic nodule in a patient with liver cirrhosis. World J
Gastroenterol. 13:3259–3261. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Otsuka T, Hagiwara S, Tojima H, Yoshida H,
Takahashi T, Nagasaka K, Tomioka S, Ando T, Takeuchi K, Kori T, et
al: Hepatocellular carcinoma with peritoneal dissemination which
was regressed during vitamin K2 and vitamin E administration.
Intern Med. 46:711–715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyazawa K, Nishimaki J, Ohyashiki K,
Enomoto S, Kuriya S, Fukuda R, Hotta T, Teramura M, Mizoguchi H,
Uchiyama T and Omine M: Vitamin K2 therapy for myelodysplastic
syndromes (MDS) and post-MDS acute myeloid leukemia: Information
through a questionnaire survey of multi-center pilot studies in
Japan. Leukemia. 14:1156–1157. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sada E, Abe Y, Ohba R, Tachikawa Y,
Nagasawa E, Shiratsuchi M and Takayanagi R: Vitamin K2 modulates
differentiation and apoptosis of both myeloid and erythroid
lineages. Eur J Haematol. 85:538–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Habu D, Shiomi S, Tamori A, Takeda T,
Tanaka T, Kubo S and Nishiguchi S: Role of vitamin K2 in the
development of hepatocellular carcinoma in women with viral
cirrhosis of the liver. JAMA. 292:358–361. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kojima K, Tamano M, Akima T, Hashimoto T,
Kuniyoshi T, Maeda C, Majima Y, Kusano K, Murohisa T, Iijima M and
Hiraishi H: Effect of vitamin K2 on the development of
hepatocellular carcinoma in type C cirrhosis.
Hepatogastroenterology. 57:1264–1267. 2010.PubMed/NCBI
|
|
16
|
Mizuta T, Ozaki I, Eguchi Y, Yasutake T,
Kawazoe S, Fujimoto K and Yamamoto K: The effect of menatetrenone,
a vitamin K2 analog, on disease recurrence and survival in patients
with hepatocellular carcinoma after curative treatment: A pilot
study. Cancer. 106:867–872. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kakizaki S, Sohara N, Sato K, Suzuki H,
Yanagisawa M, Nakajima H, Takagi H, Naganuma A, Otsuka T, Takahashi
H, et al: Preventive effects of vitamin K on recurrent disease in
patients with hepatocellular carcinoma arising from hepatitis C
viral infection. J Gastroenterol Hepatol. 22:518–522. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ishizuka M, Kubota K, Shimoda M, Kita J,
Kato M, Park KH and Shiraki T: Effect of menatetrenone, a vitamin
k2 analog, on recurrence of hepatocellular carcinoma after surgical
resection: A prospective randomized controlled trial. Anticancer
Res. 32:5415–5420. 2012.PubMed/NCBI
|
|
19
|
Zhong JH, Mo XS, Xiang BD, Yuan WP, Jiang
JF, Xie GS and Li LQ: Postoperative use of the chemopreventive
vitamin K2 analog in patients with hepatocellular carcinoma. PLoS
One. 8:580822013. View Article : Google Scholar
|
|
20
|
Yoshiji H, Kuriyama S, Noguchi R, Yoshii
J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Masaki T
and Fukui H: Combination of vitamin K2 and the
angiotensin-converting enzyme inhibitor, perindopril, attenuates
the liver enzyme-altered preneoplastic lesions in rats via
angiogenesis suppression. J Hepatol. 42:687–693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Zhang B, Zhang A, Zhao Y, Zhao J,
Liu J, Gao J, Fang D and Rao Z: Synergistic growth inhibition by
sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
Clinics. 67:1093–1099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sakakima Y, Hayakawa A, Nagasaka T and
Nakao A: Prevention of hepatocarcinogenesis with
phosphatidylcholine and menaquinone-4: In vitro and in vivo
experiments. J Hepatol. 47:83–92. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ozaki I, Zhang H, Mizuta T, Ide Y, Eguchi
Y, Yasutake T, Sakamaki T, Pestell RG and Yamamoto K:
Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular
carcinoma cell growth by suppressing cyclin D1 expression through
inhibition of nuclear factor kappaB activation. Clin Cancer Res.
13:2236–2245. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xia J, Matsuhashi S, Hamajima H, Iwane S,
Takahashi H, Eguchi Y, Mizuta T, Fujimoto K, Kuroda S and Ozaki I:
The role of PKC isoforms in the inhibition of NF-kappaB activation
by vitamin K2 in human hepatocellular carcinoma cells. J Nutr
Biochem. 23:1668–1675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sibayama-Imazu T, Fujisawa Y, Masuda Y,
Aiuchi T, Nakajo S, Itabe H and Nakaya K: Induction of apoptosis in
PA-1 ovarian cancer cells by vitamin K2 is associated with an
increase in the level of TR3/Nur77 and its accumulation in
mitochondria and nuclei. J Cancer Res Clin Oncol. 134:803–812.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Showalter SL, Wang Z, Costantino CL,
Witkiewicz AK, Yeo CJ, Brody JR and Carr BI: Naturally occurring K
vitamins inhibit pancreatic cancer cell survival through a
caspase-dependent pathway. J Gastroenterol Hepatol. 25:738–744.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Enomoto M, Tsuchida A, Miyazawa K,
Yokoyama T, Kawakita H, Tokita H, Naito M, Itoh M, Ohyashiki K and
Aoki T: Vitamin K2-induced cell growth inhibition via autophagy
formation in cholangiocellular carcinoma cell lines. Int J Mol Med.
20:801–808. 2007.PubMed/NCBI
|
|
28
|
Miyazawa K, Yaguchi M, Funato K, Gotoh A,
Kawanishi Y, Nishizawa Y, You A and Ohyashiki K:
Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60
cells: Dichotomous nature of vitamin K2 in leukemia cells.
Leukemia. 15:1111–1117. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Karin M and Ben-Neriah Y: Phosphorylation
meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev
Immunol. 18:621–663. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H,
Watanabe S, et al: Cyclins and cyclin-dependent kinases:
Comparative study of hepatocellular carcinoma versus cirrhosis.
Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Karin M and Delhase M: The I kappa B
kinase (IKK) and NF-kappa B: Key elements of proinflammatory
signalling. Semin Immunol. 12:85–98. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Holden NS, Squires PE, Kaur M, Bland R,
Jones CE and Newton R: Phorbol ester-stimulated NF-kappaB-dependent
transcription: Roles for isoforms of novel protein kinase C. Cell
Signal. 20:1338–1348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Otsuka M, Kato N, Shao RX, Hoshida Y,
Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T
and Omata M: Vitamin K2 inhibits the growth and invasiveness of
hepatocellular carcinoma cells via protein kinase A activation.
Hepatology. 40:243–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu W, Nakamura H, Yamamoto T, Ikeda N,
Saito M, Ohno M, Hara N, Imanishi H, Shimomura S, Yamamoto T, et
al: Vitamin K2 inhibits the proliferation of HepG2 cells by
up-regulating the transcription of p21 gene. Hepatol Res.
37:360–365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maniwa Y, Kasukabe T and Kumakura S:
Vitamin K2 and cotylenin A synergistically induce monocytic
differentiation and growth arrest along with the suppression of
c-MYC expression and induction of cyclin G2 expression in human
leukemia HL-60 cells. Int J Oncol. 47:473–480. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamamoto T, Nakamura H, Liu W, Cao K,
Yoshikawa S, Enomoto H, Iwata Y, Koh N, Saito M, Imanishi H, et al:
Involvement of hepatoma-derived growth factor in the growth
inhibition of hepatocellular carcinoma cells by vitamin K(2). J
Gastroenterol. 44:228–235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaneda M, Zhang D, Bhattacharjee R,
Nakahama K, Arii S and Morita I: Vitamin K2 suppresses malignancy
of HuH7 hepatoma cells via inhibition of connexin 43. Cancer Lett.
263:53–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Trosko JE: The role of stem cells and gap
junctions as targets for cancer chemoprevention and chemotherapy.
Biomed Pharmacother. 59 Suppl 2:S326–S331. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Karasawa S, Azuma M, Kasama T, Sakamoto S,
Kabe Y, Imai T, Yamaguchi Y, Miyazawa K and Handa H: Vitamin K2
covalently binds to Bak and induces Bak-mediated apoptosis. Mol
Pharmacol. 83:613–620. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shibayama-Imazu T, Sonoda I, Sakairi S,
Aiuchi T, Ann WW, Nakajo S, Itabe H and Nakaya K: Production of
superoxide and dissipation of mitochondrial transmembrane potential
by vitamin K2 trigger apoptosis in human ovarian cancer TYK-nu
cells. Apoptosis. 11:1535–1543. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsujioka T, Miura Y, Otsuki T, Nishimura
Y, Hyodoh F, Wada H and Sugihara T: The mechanisms of vitamin
K2-induced apoptosis of myeloma cells. Haematologica. 91:613–619.
2006.PubMed/NCBI
|
|
42
|
Nishimaki J, Miyazawa K, Yaguchi M,
Katagiri T, Kawanishi Y, Toyama K, Ohyashiki K, Hashimoto S, Nakaya
K and Takiguchi T: Vitamin K2 induces apoptosis of a novel cell
line established from a patient with myelodysplastic syndrome in
blastic transformation. Leukemia. 13:1399–1405. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kanamori T, Shimizu M, Okuno M,
Matsushima-Nishiwaki R, Tsurumi H, Kojima S and Moriwaki H:
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in
human hepatocellular carcinoma cells. Cancer Sci. 98:431–437. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Olson JM and Hallahan AR: p38 MAP kinase:
A convergence point in cancer therapy. Trends Mol Med. 10:125–129.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li L, Qi Z, Qian J, Bi F, Lv J, Xu L,
Zhang L, Chen H and Jia R: Induction of apoptosis in hepatocellular
carcinoma Smmc-7721 cells by vitamin K(2) is associated with p53
and independent of the intrinsic apoptotic pathway. Mol Cell
Biochem. 342:125–131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Meek DW: Tumour suppression by p53: A role
for the DNA damage response? Nat Rev Cancer. 9:714–723. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Muzio M, Stockwell BR, Stennicke HR,
Salvesen GS and Dixit VM: An induced proximity model for caspase-8
activation. J Biol Chem. 273:2926–2930. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yokoyama T, Miyazawa K, Naito M, Toyotake
J, Tauchi T, Itoh M, You A, Hayashi Y, Georgescu MM, Kondo Y, et
al: Vitamin K2 induces autophagy and apoptosis simultaneously in
leukemia cells. Autophagy. 4:629–640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ide Y, Zhang H, Hamajima H, Kawaguchi Y,
Eguchi Y, Mizuta T, Yamamoto K, Fujimoto K and Ozaki I: Inhibition
of matrix metalloproteinase expression by menatetrenone, a vitamin
K2 analogue. Oncol Rep. 22:599–604. 2009.PubMed/NCBI
|
|
50
|
Karin M: The regulation of AP-1 activity
by mitogen-activated protein kinases. Philos Trans R Soc Lond B
Biol Sci. 351:127–134. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang H, Ozaki I, Hamajima H, Iwane S,
Takahashi H, Kawaguchi Y, Eguchi Y, Yamamoto K and Mizuta T:
Vitamin K2 augments 5-fluorouracil-induced growth inhibition of
human hepatocellular carcinoma cells by inhibiting NF-κB
activation. Oncol Rep. 25:159–166. 2011.PubMed/NCBI
|
|
52
|
Funato K, Miyazawa K, Yaguchi M, Gotoh A
and Ohyashiki K: Combination of 22-oxa-1,25-dihydroxyvitamin D(3),
a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically
enhances cell differentiation but suppresses VK2-inducing apoptosis
in HL-60 cells. Leukemia. 16:1519–1527. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Iguchi T, Miyazawa K, Asada M, Gotoh A,
Mizutani S and Ohyashiki K: Combined treatment of leukemia cells
with vitamin K2 and 1alpha,25-dihydroxy vitamin D3 enhances
monocytic differentiation along with becoming resistant to
apoptosis by induction of cytoplasmic p21CIP1. Int J Oncol.
27:893–900. 2005.PubMed/NCBI
|
|
54
|
Nimptsch K, Rohrmann S, Kaaks R and
Linseisen J: Dietary vitamin K intake in relation to cancer
incidence and mortality: Results from the Heidelberg cohort of the
European Prospective Investigation into cancer and nutrition
(EPIC-Heidelberg). Am J Clin Nutr. 91:1348–1358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yoshiji H, Kuriyama S, Noguchi R, Yoshii
J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Akahane
T, et al: Amelioration of carcinogenesis and tumor growth in the
rat liver by combination of vitamin K2 and angiotensin-converting
enzyme inhibitor via anti-angiogenic activities. Oncol Rep.
15:155–159. 2006.PubMed/NCBI
|
